Overview
Qualitative or quantitative defects of fukutin refer to a group of rare genetic disorders caused by mutations in the FKTN gene, which encodes the protein fukutin. Fukutin plays a critical role in the glycosylation of alpha-dystroglycan, a protein essential for maintaining the structural integrity of muscle fibers and proper brain development. Defects in fukutin lead to a spectrum of conditions collectively classified as dystroglycanopathies, most notably Fukuyama congenital muscular dystrophy (FCMD), as well as milder limb-girdle muscular dystrophy type 2M (LGMD R13) and more severe Walker-Warburg syndrome or muscle-eye-brain disease phenotypes. These conditions primarily affect the skeletal muscles, the brain, and the eyes. Key clinical features include progressive muscular weakness and wasting, intellectual disability, seizures, structural brain abnormalities (such as cobblestone lissencephaly and cerebellar cysts), and ocular abnormalities including retinal detachment and myopia. In the most severe forms, such as Walker-Warburg syndrome, affected infants present at birth with profound hypotonia, severe brain malformations, and eye defects, often with a significantly shortened lifespan. Fukuyama congenital muscular dystrophy, the most common form in Japan, typically presents in early infancy with generalized hypotonia, poor feeding, weak cry, and delayed motor milestones. Most affected children never achieve independent ambulation. There is currently no cure for fukutin-related dystroglycanopathies. Treatment is supportive and multidisciplinary, involving physical therapy to maintain mobility, management of seizures with antiepileptic medications, respiratory support as needed, nutritional support, and ophthalmologic and cardiac monitoring. Orthopedic interventions may be required for contractures and scoliosis. Research into gene therapy and pharmacological approaches to restore alpha-dystroglycan glycosylation is ongoing but remains experimental.
Autosomal recessive
Passed on when both parents carry the same gene change; often skips generations
Variable
Can begin at different ages, from infancy through adulthood
Treatments
No FDA-approved treatments are currently listed for Qualitative or quantitative defects of fukutin.
View clinical trials →Clinical Trials
View all trials with filters →No actively recruiting trials found for Qualitative or quantitative defects of fukutin at this time.
New trials open frequently. Follow this disease to get notified.
Specialists
View all specialists →No specialists are currently listed for Qualitative or quantitative defects of fukutin.
Treatment Centers
8 centersBaylor College of Medicine Rare Disease Center ↗
Baylor College of Medicine
📍 Houston, TX
🏥 NORDStanford Medicine Rare Disease Center ↗
Stanford Medicine
📍 Stanford, CA
🔬 UDNNIH Clinical Center Undiagnosed Diseases Program ↗
National Institutes of Health
📍 Bethesda, MD
🔬 UDNUCLA UDN Clinical Site ↗
UCLA Health
📍 Los Angeles, CA
🔬 UDNBaylor College of Medicine UDN Clinical Site ↗
Baylor College of Medicine
📍 Houston, TX
🔬 UDNHarvard/MGH UDN Clinical Site ↗
Massachusetts General Hospital
📍 Boston, MA
🏥 NORDMayo Clinic Center for Individualized Medicine ↗
Mayo Clinic
📍 Rochester, MN
👤 Mayo Clinic Center for Individualized Medicine
🏥 NORDUCLA Rare Disease Day Program ↗
UCLA Health
📍 Los Angeles, CA
Travel Grants
No travel grants are currently matched to Qualitative or quantitative defects of fukutin.
Community
No community posts yet. Be the first to share your experience with Qualitative or quantitative defects of fukutin.
Start the conversation →Latest news about Qualitative or quantitative defects of fukutin
No recent news articles for Qualitative or quantitative defects of fukutin.
Follow this condition to be notified when news becomes available.
Caregiver Resources
NORD Caregiver Resources
Support, advocacy, and financial assistance for caregivers of rare disease patients.
Mental Health Support
Rare disease caregiving can be isolating. Connect with counseling and peer support.
Family & Caregiver Grants
Financial assistance programs specifically for caregivers of rare disease patients.
Social Security Disability
Learn how rare disease patients may qualify for SSDI/SSI benefits.
Common questions about Qualitative or quantitative defects of fukutin
What is Qualitative or quantitative defects of fukutin?
Qualitative or quantitative defects of fukutin refer to a group of rare genetic disorders caused by mutations in the FKTN gene, which encodes the protein fukutin. Fukutin plays a critical role in the glycosylation of alpha-dystroglycan, a protein essential for maintaining the structural integrity of muscle fibers and proper brain development. Defects in fukutin lead to a spectrum of conditions collectively classified as dystroglycanopathies, most notably Fukuyama congenital muscular dystrophy (FCMD), as well as milder limb-girdle muscular dystrophy type 2M (LGMD R13) and more severe Walker-War
How is Qualitative or quantitative defects of fukutin inherited?
Qualitative or quantitative defects of fukutin follows a autosomal recessive inheritance pattern. Genetic counseling can help families understand recurrence risk and testing options.